Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales
This article was originally published in The Tan Sheet
Johnson & Johnson's consumer products sales jumped 48.5 percent to $3.49 billion in the firm's first fiscal quarter since closing its acquisition of Pfizer Consumer Healthcare
You may also be interested in...
Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business
Boehringer Ingelheim looks to expand its therapeutic territory up the GI tract with a $509.5 mil. purchase of U.S. rights to the acid reducer Zantac (ranitidine) from Johnson & Johnson and the Pfizer Consumer Healthcare business
Chattem said its past experience with brands such as Icy Hot and Selsun Blue will make for an easier transition of its newest package acquisition